Peptide Therapeutics Market: Advancing Targeted Treatments, Precision Medicine, and Innovative Drug Development

The global Peptide Therapeutics Market is expanding as pharmaceutical and biotechnology companies increasingly focus on targeted treatments, advanced drug development, and personalized medicine. Peptide therapeutics are medicines developed from short chains of amino acids that can interact with specific biological targets. They are used across several therapeutic areas, including metabolic disorders, cancer, gastrointestinal conditions, cardiovascular diseases, and certain infectious and neurological disorders.

According to Kings Research, the global peptide therapeutics market was valued at USD 42.52 billion in 2023 and is projected to grow from USD 45.61 billion in 2024 to USD 83.83 billion by 2031, registering a compound annual growth rate of 9.08% from 2024 to 2031.

The growing prevalence of chronic diseases, increasing investment in pharmaceutical research, and improvements in peptide synthesis and drug delivery technologies are supporting market expansion. Pharmaceutical companies are also exploring peptides as alternatives or complements to traditional small-molecule drugs and other biologic therapies.

Advances in computational drug discovery, formulation science, and large-scale manufacturing are creating new opportunities for peptide-based medicines. These developments are helping researchers improve drug stability, therapeutic selectivity, and delivery while expanding the range of conditions that peptide therapeutics may address.

Rising Demand for Targeted and Effective Therapies

The increasing demand for targeted treatments is a major factor driving the peptide therapeutics market. Many conventional medicines can affect multiple biological pathways, potentially leading to unwanted effects. Peptides can be designed to interact with particular receptors, enzymes, or other biological targets, making them valuable candidates for developing more selective therapies.

Their biological activity and structural flexibility allow researchers to modify peptide sequences to improve binding, stability, and therapeutic performance. Depending on their design, peptide-based medicines can influence hormone signaling, immune responses, metabolic processes, and other functions involved in disease development.

The growing burden of chronic conditions is creating opportunities across several therapeutic areas. Diabetes, obesity, cardiovascular disorders, cancer, and gastrointestinal diseases are receiving substantial attention from pharmaceutical developers because they often require long-term treatment and continued improvements in therapeutic outcomes.

As researchers develop peptides with enhanced selectivity and longer-lasting activity, the technology is expected to remain an important part of pharmaceutical innovation.

Innovative Peptide Drugs Expand Market Opportunities

The market is segmented by type into generic and innovative peptide therapeutics. The innovative segment generated USD 26.43 billion in revenue in 2023, reflecting the importance of newly developed peptide medicines in the industry.

Innovative therapies are designed to address unmet medical needs through new molecular structures, improved formulations, alternative delivery methods, or different mechanisms of action. Pharmaceutical companies are investing in research to develop peptides with better stability, longer duration of action, and improved patient convenience.

Innovation is particularly important in areas where existing treatments may not provide sufficient disease control or may require frequent administration. Researchers are exploring modified peptide sequences and formulation strategies that can improve the way medicines behave within the body.

The development of novel peptide drugs also creates opportunities for biotechnology companies, contract research organizations, and specialist manufacturers. These organizations can contribute expertise in peptide design, laboratory testing, clinical development, and commercial-scale production.

Injectable Administration Remains Important

By route of administration, the market includes parenteral, oral, and other delivery methods. The parenteral segment accounted for 41.79% of the market in 2023 and is projected to reach USD 34.66 billion by 2031.

Injectable administration remains important because many peptides are vulnerable to degradation in the digestive system. Some may also have limited absorption when taken orally, making injections a practical option for delivering the required dose.

Parenteral formulations can support predictable drug delivery and are widely used for peptide medicines targeting metabolic, hormonal, and other conditions. However, frequent injections may be inconvenient for some patients and can affect treatment adherence.

To address these limitations, researchers are developing longer-acting formulations, improved injection devices, and alternative delivery technologies. Oral peptide formulations are also receiving attention, although achieving sufficient stability and absorption remains technically challenging for many compounds.

Advances in formulation and delivery are expected to influence the competitive position of peptide therapeutics by improving convenience and expanding their potential applications.

Metabolic Disorders Create Significant Growth Opportunities

Metabolic disorders are an important area of development for peptide therapeutics. Conditions such as diabetes and obesity affect large patient populations and often require long-term management.

Certain peptide medicines act on hormonal pathways involved in glucose regulation, appetite, digestion, and energy balance. These mechanisms have contributed to the growing role of peptide-based treatments in metabolic healthcare.

The increasing focus on obesity management and diabetes care is encouraging pharmaceutical companies to develop therapies with improved efficacy, longer duration of action, and more convenient dosing schedules. Researchers are also investigating combinations of biological targets to improve treatment outcomes.

The commercial success of peptide-based metabolic medicines has encouraged further investment in research, manufacturing capacity, and drug delivery systems. As competition increases, companies are seeking to differentiate products through dosing frequency, tolerability, treatment convenience, and clinical performance.

However, treatment decisions depend on individual patient needs, approved indications, and clinical guidance. Continued research and regulatory evaluation remain essential for establishing the safety and effectiveness of new peptide therapies.

Applications in Cancer and Gastrointestinal Disorders

Cancer treatment represents another important area for peptide therapeutic research. Peptides can be designed to recognize particular molecular targets, making them useful candidates for targeted drug delivery and other oncology applications.

Researchers are investigating peptide-based approaches for improving the delivery of therapeutic agents to cancer cells while limiting exposure to healthy tissues. Peptides are also being studied as components of cancer vaccines and other immunotherapy strategies.

These applications remain diverse in their level of clinical development, and not every research candidate will become an approved treatment. Nevertheless, continued progress in molecular targeting and drug design is expanding the possibilities for peptide-based oncology products.

Gastrointestinal disorders also represent a substantial opportunity. Kings Research projects that the gastrointestinal disorders segment will reach USD 23.97 billion by 2031. Peptides can influence digestive processes, hormonal signaling, and other mechanisms relevant to gastrointestinal health.

Demand for treatments addressing digestive disorders, metabolic conditions associated with gastrointestinal function, and other chronic diseases is encouraging continued investment in this segment. Future growth will depend on clinical evidence, product differentiation, and the ability to manufacture reliable therapies at commercial scale.

Advances in Peptide Synthesis and Manufacturing

Manufacturing technology is a critical component of the peptide therapeutics market. Producing therapeutic peptides requires precise control over amino acid sequences, purity, molecular structure, and the removal of unwanted by-products.

Major production approaches include solid-phase peptide synthesis, liquid-phase peptide synthesis, recombinant DNA technology, and hybrid methods. Each technique has different advantages depending on peptide length, complexity, required production volume, and manufacturing economics.

Solid-phase peptide synthesis allows amino acids to be assembled in a controlled sequence while the growing peptide remains attached to a solid support. This method is widely used for producing many synthetic peptides, although reagent consumption and purification requirements can increase costs.

Liquid-phase peptide synthesis is expected to remain an important technology for large-scale manufacturing. Kings Research projects that the liquid-phase peptide synthesis segment will reach USD 22.47 billion by 2031.

Manufacturers are also exploring hybrid synthesis approaches, automation, continuous processing, and improved purification systems. These developments can help increase production efficiency, improve consistency, and reduce material waste.

As demand for peptide medicines grows, companies with strong technical capabilities and reliable manufacturing infrastructure are likely to play an increasingly important role in the market.

Artificial Intelligence Transforms Peptide Drug Discovery

Artificial intelligence and computational technologies are creating new opportunities in peptide research. Traditional drug discovery can involve extensive laboratory experimentation, repeated molecular modification, and lengthy testing processes.

AI-based platforms can analyze biological datasets, evaluate molecular structures, and help researchers identify peptide candidates with promising properties. Machine learning models can also support the prediction of molecular interactions and guide the optimization of peptide sequences.

In May 2023, Fujitsu launched its Biodrug Design Accelerator platform in collaboration with PeptiDream. The platform was developed to improve peptide drug discovery by connecting design, synthesis, testing, and analysis activities within a centralized research workflow.

In January 2025, Pepticom secured USD 6.6 million in Series A1 funding to advance its AI-driven peptide drug discovery platform.

These developments illustrate the growing interest in combining computational methods with experimental research. AI does not eliminate the need for laboratory testing or clinical trials, but it can help researchers prioritize candidates and organize development activities more efficiently.

As these technologies mature, their contribution to peptide discovery and optimization is expected to increase.

High Production Costs and Scalability Challenges

Despite its growth potential, the peptide therapeutics market faces manufacturing and commercialization challenges. Producing high-purity peptides can require specialized raw materials, sophisticated equipment, multiple purification stages, and rigorous quality-control procedures.

Longer or structurally complex peptides may be particularly difficult to manufacture efficiently. Some compounds are also susceptible to degradation or aggregation, creating additional requirements for formulation, storage, and transportation.

Scaling a production process from laboratory research to commercial manufacturing can introduce further difficulties. Manufacturers must demonstrate that the process can consistently deliver products meeting strict quality standards while maintaining acceptable costs and production capacity.

The industry is responding through investments in manufacturing facilities, improved synthesis technologies, automated processing, and specialized contract development and manufacturing services.

In July 2024, CordenPharma announced a USD 973 million investment to expand peptide manufacturing capabilities in the United States and Europe. Such investments reflect the need for additional capacity as pharmaceutical companies advance peptide-based drug candidates and commercial products.

Regional Analysis of the Peptide Therapeutics Market

North America held the largest regional share of the peptide therapeutics market in 2023, accounting for 33.24%, equivalent to approximately USD 14.13 billion. The region benefits from established pharmaceutical companies, advanced biotechnology research, substantial healthcare expenditure, and a strong clinical development ecosystem.

The United States is a major contributor because of its pharmaceutical research infrastructure, investment in innovative medicines, and access to specialized manufacturing and clinical research capabilities.

Asia Pacific is expected to be the fastest-growing regional market, with a projected CAGR of 9.95% during the forecast period. Kings Research estimates that the regional market will reach USD 19.28 billion by 2031.

Growth across Asia Pacific is supported by expanding pharmaceutical manufacturing, increasing healthcare investment, rising demand for chronic disease treatments, and improvements in biotechnology research. China, India, Japan, and South Korea are important participants in the regional pharmaceutical ecosystem.

Europe also remains a significant market, supported by established pharmaceutical companies, contract manufacturing organizations, research institutions, and regulatory infrastructure. Continued investment in peptide synthesis and biologic drug development is expected to create opportunities across major regional markets.

Regulatory Requirements and Quality Standards

Regulatory oversight is essential to the development and commercialization of peptide therapeutics. Manufacturers must demonstrate product quality, safety, and efficacy through appropriate analytical testing, preclinical research, and clinical studies.

In the United States, the Food and Drug Administration oversees the approval of peptide medicines. In Europe, the European Medicines Agency and national regulatory authorities assess medicinal products under applicable European frameworks. Japan's Pharmaceuticals and Medical Devices Agency plays a key role in reviewing medicines, while India's Central Drugs Standard Control Organisation oversees relevant pharmaceutical approvals.

Manufacturers must also comply with applicable good manufacturing practice requirements, which cover production controls, documentation, quality assurance, and facility operations.

Regulatory expectations can influence development timelines and costs, particularly for innovative compounds and complex formulations. Companies that establish strong quality systems early in development may be better positioned to move products through clinical evaluation and commercial manufacturing.

Competitive Landscape and Industry Developments

The peptide therapeutics market includes pharmaceutical companies, biotechnology innovators, specialist peptide manufacturers, and contract development and manufacturing organizations. Key companies identified by Kings Research include AbbVie, Novartis, Pfizer, Eli Lilly and Company, Roche, Novo Nordisk, PeptiDream, Takeda Pharmaceutical Company, Bachem, Assia Chemical Industries, AstraZeneca, CordenPharma, Debiopharm, GlaxoSmithKline, and Hanmi Pharmaceutical.

Competition is shaped by research investment, intellectual property, clinical results, manufacturing capacity, and the ability to commercialize medicines for large patient populations.

In July 2024, AstraZeneca completed its acquisition of Amolyt Pharma, strengthening its portfolio in rare endocrine diseases through the investigational peptide therapy eneboparatide.

In March 2025, AbbVie and Gubra entered into a licensing agreement concerning GUB014295, a long-acting amylin analog being developed for obesity treatment. The agreement highlights the industry's continued interest in peptide-based approaches to metabolic disease.

Partnerships between drug developers and specialist manufacturers are also important. These collaborations can provide access to synthesis expertise, process development, scale-up facilities, and commercial production capabilities.

Future Outlook of the Peptide Therapeutics Market

The future of the peptide therapeutics market will be shaped by innovation in drug discovery, formulation science, precision medicine, and manufacturing technology.

AI-assisted molecular design is expected to help researchers identify and optimize promising peptide candidates. At the same time, advances in long-acting formulations and alternative delivery systems may improve patient convenience and broaden the potential use of peptide medicines.

Metabolic disorders, oncology, gastrointestinal diseases, and rare conditions are expected to remain important areas of research and commercialization. Growing demand for peptide-based medicines will also encourage further investment in production facilities and specialized manufacturing services.

However, market participants will need to address production costs, stability limitations, clinical development risks, and regulatory requirements. Companies that combine strong research capabilities with reliable manufacturing and well-defined therapeutic applications are likely to be better positioned for long-term growth.

Conclusion

The Peptide Therapeutics Market is becoming an increasingly important part of pharmaceutical innovation as demand grows for targeted treatments and advanced drug development. The market is projected to expand from USD 45.61 billion in 2024 to USD 83.83 billion by 2031, registering a CAGR of 9.08%.

Advances in peptide synthesis, AI-driven discovery, drug delivery, and large-scale manufacturing are creating opportunities across metabolic disorders, cancer, gastrointestinal conditions, and other therapeutic areas. North America currently leads the market, while Asia Pacific is expected to experience faster growth during the forecast period.

Although manufacturing costs, scalability, stability, and regulatory requirements remain important challenges, continued investment and collaboration are strengthening the industry's development pipeline. As pharmaceutical companies pursue more targeted and effective treatments, peptide therapeutics are expected to maintain a significant role in the evolution of modern medicine.